Noxopharm is an Australian clinical-stage drug development company listed on the Australian Securities Exchange (ASX: NOX) since 2016. It was founded by one of Australia's pioneering cancer researchers, Dr Graham Kelly and was the third of four public companies founded by him. The fourth public company was Nyrada, Inc. (ASX:NYR), active in the areas of drug development for cardiovascular and neurological diseases which listed on the ASX in January 2020. Pharmorage is a privately held, fully owned subsidiary of Noxopharm.
Noxopharm’s lead drug candidate Veyonda® (also known as NOX66) is being developed as a treatment for various cancers and has already advanced to phase 2 clinical trials. It is also being investigated as a treatment for septic shock.
As a potential treatment for septic shock, Veyonda’s active compound (idronoxil) has also been shown in pre-clinical studies to play an important role in helping to block some of the hyper-inflammatory processes involved in the cytokine release syndrome appearing in patients with COVID-19 and other inflammatory conditions. A clinical trial program into Veyonda for use with COVID-19 patients in currently underway.
Noxopharm’s work into modulating inflammatory responses has given rise to the genesis of Pharmorage, dedicated to meeting the enormous unmet needs for effective therapeutics for acute and chronic inflammation, autoimmune disorders and effective, safe mRNA therapeutics.
Veyonda® is currently not approved in Australia or any other country